A Study of GFS101A in Combination With Toripalimab in Patients With Advanced Solid Tumors
Launched by ZHEJIANG GENFLEET THERAPEUTICS CO., LTD. · Dec 16, 2021
Trial Information
Current as of May 28, 2025
Withdrawn
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Voluntarily participate in this clinical trial, and are willing to sign informed consent forms.
- • 2. Male or female aged from 18-75 years old (inclusive).
- • 3. Diagnosed with histologically or cytologically confirmed advanced solid tumors.
- • 4. Evaluable lesions defined by RECIST v1.1.
- • 5. Eastern Cooperative Oncology Group performance status of 0 to 1.
- • 6. Subjects or their legal representatives are able to communicate well with Investigators and are willing to comply with the protocol and complete the study.
- Exclusion Criteria:
- • 1. With clinically significant cardiac diseases
- • 2. With clinically significant digestive disorders.
- • 3. Other severe disease.
- • 4. Pregnant or lactating women.
- • 5. Other unfavorable situations for subjects to participate in the study judged by Investigators.
About Zhejiang Genfleet Therapeutics Co., Ltd.
Zhejiang Genfleet Therapeutics Co., Ltd. is a pioneering biopharmaceutical company based in China, dedicated to the development of innovative therapies for the treatment of various diseases. Leveraging cutting-edge technologies and a robust research and development pipeline, Genfleet focuses on advancing novel drug candidates in oncology, autoimmune disorders, and other therapeutic areas. The company is committed to enhancing patient outcomes through rigorous clinical trials and a strong emphasis on scientific excellence, collaboration, and regulatory compliance. With a vision to become a leader in the global biopharmaceutical landscape, Genfleet actively seeks to address unmet medical needs with safe and effective treatments.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials